Ligand Pharmaceuticals (LGND) Change in Cash (2010 - 2026)

Ligand Pharmaceuticals has disclosed Change in Cash across 17 years of filings, most recently posting -$59.8 million for Q1 2026.

• Change in Cash for Q1 2026 came in at -$59.8 million, down 146.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.0 million (up 166.9% YoY), and the FY2025 annual result was $102.6 million, up 107.93% from the prior year.
• Change in Cash came in at -$59.8 million for Q1 2026 at Ligand Pharmaceuticals, down from $35.6 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $71.7 million in Q3 2025 to a low of -$60.3 million in Q2 2023.
• The 5-year median for Change in Cash is $3.1 million (2023), against an average of $6.4 million.
• Across the five-year window, Change in Cash soared 1146.58% in 2022 and tumbled 637.71% in 2023, its largest moves.
• Ligand Pharmaceuticals' Change in Cash stood at $40.9 million in 2022, then sank by 92.43% to $3.1 million in 2023, then surged by 180.62% to $8.7 million in 2024, then soared by 309.2% to $35.6 million in 2025, then slumped by 268.3% to -$59.8 million in 2026.
• The last three Change in Cash figures came in at -$59.8 million (Q1 2026), $35.6 million (Q4 2025), and $71.7 million (Q3 2025), per Business Quant data.